Profarma considering public offering of shares as alternative to raise funds to enable organic growth project
Profarma estuda realização de oferta pública de ações como uma alternativa para captação de recursos para viabilizar projeto de crescimento orgânico
Intel ID : 252953
Relevant Documents
| Notice / Relevant Fact | 20 Sep 2017 | Profarma_Comunicado_2017.pdf | PT |
|
| Intel ID | 252953 | |
| Value | ND | |
| Native Currency |
Brazilian Real (BRL)
Exchange Rate:  |
|
|
Financial Data - Profarma
(31 Dec 2024) |
Revenue: EUR 1.585,09m EBITDA: EUR 73,25m Net Debt: EUR 89,01m Exchange Rate: 
|
|
| Date |
|
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Issuer
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
10.01.03 Distributors & Wholesalers (B2B) 10 Business Services / 10.01 Business & Professional Support Services 15.05.08 Food & Beverage Retail 15 Consumer Products & Services / 15.05 Distribution & Retail 30.02.03 Healthcare Product Distributors 30 Healthcare / 30.02 Healthcare Equipment & Supplies |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.